Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Tixocortol pivalate** is a synthetic corticosteroid and 21-thiol derivative of hydrocortisone classified as a class A steroid, featuring topical anti-inflammatory properties with minimal systemic glucocorticoid or mineralocorticoid activity due to rapid liver metabolism and transformation in red blood cells. It acts as a glucocorticoid receptor agonist and histone deacetylase 2 stimulator, reducing inflammation locally in conditions like rhinitis, pharyngitis, and ulcerative colitis. Primarily administered via nasal sprays, lozenges, enemas, or rectal solutions, it is also used in patch testing to screen for contact allergies to class A corticosteroids and is marketed under names like Pivalone.[1][2][3][4][5][6][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tixocortol pivalate.